Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Roche CEO Severin Schwan says the process of paying for hugely expensive gene therapies that can cure diseases needs revamping.
PureTech's affiliate Gelesis has received US FDA de novo clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Italy-based Cassiopea says “very positive results” from Breezula's 12-month Phase II alopecia trial support progressing it to Phase III, particularly given the clean safety profile.
PureTech's affiliate Gelesis has received FDA clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half.
Investors during Roche’s first-quarter update Wednesday will be looking for clues on looming biosimilar competition and timelines for the emergence of promising pipeline assets.
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.